EuropeEurope.PortalSvet.Slajder

EU seals deal for 1.8 billion more BioNTech/Pfizer vaccine doses

The European Commission has struck a deal with Covid-19 vaccine producer BioNTech/Pfizer to buy up to 1.8 billion additional doses for the next few years, President Ursula von der Leyen announced on Saturday.

Brussels, 8 May 2021 (dpa/MIA) – The European Commission has struck a deal with Covid-19 vaccine producer BioNTech/Pfizer to buy up to 1.8 billion additional doses for the next few years, President Ursula von der Leyen announced on Saturday.

“Happy to announce that [the European Commission] has just approved a contract for guaranteed 900 million doses,” von der Leyen tweeted.

The deal, covering 2021-23, also allows EU states to buy a further 900 million doses, according to the top EU official. “Other contracts and other vaccine technologies will follow,” she wrote.

The EU is preparing for its future needs for booster shots, dealing with “possible escape variants” and for the vaccination of children and adolescents, von der Leyen said.

The finished deal with the joint German-US pharmaceutical venture is worth up to 35 billion euros (43 billion dollars) and will lead to further investment in Germany and Belgium, dpa understands.

The commission remains tight-lipped about the prices it pays its various suppliers per dose, but Bulgarian Prime Minister Boyko Borisov said earlier this month that the cost of each shot in the new deal was around 19.50 euros, higher than in previous contracts.
EU sources confirmed that the cost of each dose was under 20 euros.

Two shots are needed for vaccination.

The EU already has two supply contracts with BioNTech/Pfizer for 600 million vaccine doses. Deliveries started at the end of 2020. The bloc is expecting 250 million vaccine doses from the manufacturers from the beginning of April to the end of June.

The messenger ribonucleic acid (mRNA) vaccine was the first to be authorized for use in the bloc, and has not been linked so far with a potential blood clotting risk unlike the jabs made by AstraZeneca and Johnson & Johnson. These two are prepared differently, using so-called adenoviruses.

One advantage of new mRNA technology is that vaccines can also be adapted relatively quickly to virus mutations, which will likely be important for booster vaccinations.

The downside is that drug has to be stored at extremely cold temperatures and that it is more expensive than those made by AstraZeneca and Johnson & Johnson.

The EU executive announced on April 14 that negotiations on the contract were under way, with von der Leyen saying the European Union needed to concentrate on technologies that had proven their worth.

The commission chief also said previously that as part of the agreement with the drugmakers manufacturing would be entirely in the EU, not just for the vaccine but also for all its ingredients.

Until now, the supply chains for raw materials have been dispersed across the globe, with manufacturers sometimes facing issues obtaining ingredients.

Провери го и ова

Close
Back to top button
Close
Close